Journal article

A Canadian genome-wide association study and meta-analysis confirm HLA as a risk factor for peanut allergy independent of asthma

Yuka Asai, Aida Eslami, C Dorien van Ginkel, Loubna Akhabir, Ming Wan, David Yin, George Ellis, Moshe Ben-Shoshan, Ingo Marenholz, David Martino, Manuel A Ferreira, Katrina Allen, Bruce Mazer, Hans de Groot, Nicolette W de Jong, Roy Gerth van Wijk, Anthony EJ Dubois, Sarah Grosche, Sarah Ashley, Franz Rueschendorf Show all

Journal of Allergy and Clinical Immunology | MOSBY-ELSEVIER | Published : 2018


Awarded by National Institutes of Health

Awarded by US Department of Defense

Awarded by Ministry of Economic Affairs

Funding Acknowledgements

Supported by the Allergy, Genes, and Environment Network of Centres of Excellence (AllerGen NCE), Canadian Institutes of Health Research, Canadian Research Chairs Program (salary award to D.D.), Natural Sciences and Engineering Research Council and Michael Smith Foundation for Health Research/AllerGen NCE postdoctoral research fellowship awards (to A.E.), Division of Experimental Medicine Entrance Fellowship (to Y.A.), Montreal Children's Hospital Foundation, McGill University Health Centre Foundation, Canadian Dermatology Foundation, Canadian Allergy, Asthma and Immunology Foundation, Canadian Society of Allergy and Clinical Immunology, the National Institutes of Health (grant no. CA112355 awarded to J.S.W. and RC2 AG036607 awarded to C.A. Schaefer and N.J. Risch), HealthWay, National Health and Medical Research Council (Australia), Australian Research Council, US Department of Defense (grant no. W81XWH-10-1-0487), and a Clinical Exchange Program fellowship of the Experimental and Clinical Research Center of Max Delbruck Center and Charite Medical School. C.D.v.G., A.E.J.D., and G.H.K. received an unrestricted grant from the Nutricia Research Foundation to complete the Dutch GENEVA cohort. The Dutch IDEAL cohort of N.W.d.J., H.d.G., R.G.v.W., and A.E.J.D. was supported by the Dutch Technology Foundation STW, which is part of the Netherlands Organisation for Scientific Research (NOW) and funded in part by the Ministry of Economic Affairs (project number 11868) and Food Allergy Foundation, Siemens Healthcare Diagnostics, HAL Allergy, Intersnack the Netherlands B.V., ALK-Albello B.V., and the Netherlands Anaphylaxis Network. Funding sources had no role in study design, collection, analysis and interpretation of data or in the decision to submit or writing of the report. The Genotype-Tissue Expression Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by the National Cancer Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute of Drug Abuse; National Institute of Mental Health; and National Institute of Neurological Disorders and Stroke. The data used for the analyses described in this manuscript were obtained from the Genotype-Tissue Expression Project Portal on January 1, 2017, to February 28, 2017.